Navigation Links
Experimental vaccine protects lab animals against several strains of H5N1

Nations are preparing to stockpile vaccines against H5N1, the strain of influenza virus that experts fear could cause the next flu pandemic. But will these vaccines remain effective as the virus mutates? Researchers present good news in the July 15 issue of The Journal of Infectious Diseases, now available online.

Elena Govorkova, MD, PhD, Robert G. Webster, PhD, and coworkers at St. Jude Children's Research Hospital in Memphis, Tenn., used reverse genetics to develop an influenza virus with two key proteins on its surface derived from an H5N1 strain. They inactivated the virus and used it to vaccinate ferrets. The vaccine protected the ferrets from getting sick when exposed not only to the flu strain from which the vaccine was made, but also two other strains, including a deadly strain labeled A/Vietnam/1203/04.

Cross-strain protection is exactly what one would need, as it would protect against newly emerging variants until a strain-specific vaccine can be developed. The reverse genetics method used by the St. Jude investigators would allow rapid vaccine preparation, which is crucial in a potentially fast-moving pandemic. Other undertaken vaccine approaches have serious shortcomings. Wild-type H5N1 vaccines, for example, cannot be produced on a large scale because of their marked virulence, and vaccines based on less-virulent H5N1 strains have so far been relatively poor stimulators of immunity in human trials.

In the study, the ferrets were vaccinated intramuscularly with one or two doses of vaccine. Both schedules induced a protective antibody response, but the two-dose schedule induced higher levels of antibodies that were cross-reactive to various H5N1 viruses. Human clinical trials have seen similar results, suggesting that two doses of vaccine will be required to effectively protect against an H5N1 flu strain.

In an accompanying editorial, Alan W. Hampson, MSc, of the Australian Influenza Specialist Group, noted that the succe ssful use of a genetically modified whole-virus vaccine that produced protective antibodies against H5N1 virus in ferrets suggests that the ferret model has the potential to provide useful information in assessing vaccines when human data alone are inadequate.

"Possibly the greatest significance of the current study, he added, "is the demonstration of a significant cross-strain protective effect," a finding that "strengthens the argument for stockpiling vaccines prepared from currently available H5N1 vaccine strains."


'"/>

Source:Infectious Diseases Society of America


Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
5. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
6. Experimental RNA-based drug kills prostate cancer cells effectively and safely
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Research advances quest for HIV-1 vaccine
11. A much-needed shot in the arm for HIV vaccine development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... PRAGUE, Czech Republic , February 8, 2016 ... first EU-regulated global payment platform which presents innovation ... Voice Biometrics Authentication feature called VoiceKey. --> ... payment platform which presents innovation for clients, comfort ... feature called VoiceKey. --> Worldcore ...
(Date:2/5/2016)... 5, 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ... "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ... report to their offering. --> ... has announced the addition of the ...
(Date:2/4/2016)... , Feb. 4, 2016 The field ... one of the most popular hubs of the ... and other huge studies of human microbiota, have ... few years, the microbiome space has literally exploded ... research. This report focuses on biomedical aspects ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... 2016  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced that it has entered into ... Technology Growth Capital, Inc. and Hercules Technology III, ... --> --> ... financing under the loan and security agreement.  The ...
(Date:2/8/2016)... 8, 2016 --> ... an innovation-driven oncology company developing next generation cancer ... today announced that chairman emeritus of Tata Sons ... the company as part of the first close ... investors Navam Capital and Aarin Capital. ...
(Date:2/8/2016)... Novan, Inc. today announced that Director Robert A. Ingram ... In addition, Robert Keegan has been appointed to the ... --> North Carolina . ... of $32.8 million of net proceeds in a private Mezzanine B ... the Research Triangle area of North Carolina . ...
(Date:2/8/2016)... PA (PRWEB) , ... February 08, 2016 , ... ... Center’s Board of Directors. Todorow is the Executive Vice President for Corporate Services ... CFO, Todorow oversees Finance, Accounts Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, ...
Breaking Biology Technology: